Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(5):337; doi:10.1093/jnci/95.5.337-b
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content

Journal of the National Cancer Institute, Vol. 95, No. 5, 337, March 5, 2003
© 2003 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

AIB1, HER-2/neu, and Tamoxifen Resistance

AIB1 is an estrogen receptor (ER) coactivator that, when overexpressed, can reduce the antagonist activity of tamoxifen-bound ER in breast cancer cells. AIB1 is activated by phosphorylation via signaling through the HER-2 receptor pathway. To determine whether high AIB1 expression alone or together with HER-2 reduces the effectiveness of tamoxifen, Osborne et al. (p. 353) quantified expression of AIB1 and HER-2 from breast cancer patients who either received no adjuvant therapy or adjuvant tamoxifen therapy after surgery. They found that high AIB1 expression in tumors of patients not receiving tamoxifen was associated . . . [Full Text of this Article]

Chemotherapy for Elderly Patients: the MILES Trial

Folate and Breast Cancer Risk

Cancer Risk and Cystic Fibrosis After Organ Transplantation

Induction of Antiangiogenic Activity by rt-PA and Captopril

DNA Methylation and Zebularine